timothy sykes logo
SYRE Stock Steadies As SPY003 Data Resets Biotech Expectations Thumbnail
G Google News

SYRE Stock Steadies As SPY003 Data Resets Biotech Expectations

TIM SYKES•UPDATED SEP. 30, 2026, 3:02 PM ET
Reviewed by Bryce Tuoheyand Fact-checked by Matt Monaco

Spyre Therapeutics Inc. stocks have been trading up by 5.22 percent following optimistic coverage of its pipeline and trial progress

Key Takeaways

  • Phase 2 SKYLINE data showed SPY003 hit its primary endpoint in ulcerative colitis with strong histologic gains, 20% clinical remission, and 30% endoscopic improvement on a clean safety profile.
  • The SPY003 readout completes clinical proof-of-concept for all three Spyre IBD assets, with combination Part B of SKYLINE now enrolling as the next major pipeline catalyst.
  • Shares of SYRE traded modestly lower after the positive data, signaling expectations were high and traders may be waiting for combination and later-stage results.
  • Senior Spyre executives, including the CEO, CFO, and Chief Legal Officer, sold millions of dollars’ worth of SYRE stock on 2026/09/01 but still retain meaningful holdings.
  • Spyre will hit multiple conferences in September 2026 and has additional Phase 2 readouts for SPY072 in psoriatic arthritis and axial spondyloarthritis teed up for late 2026.

Candlestick Chart

Live Update At 15:02:16 EDT: On Wednesday, September 30, 2026 Spyre Therapeutics Inc. stock [NASDAQ: SYRE] is trending up by 5.22%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Spyre Therapeutics, trading as SYRE, is a classic clinical‑stage biotech: little revenue today, big bets on the future. The latest quarter shows a net loss of $36.2M, or -$0.36 per share, driven mainly by $65.5M of research spending and $16.1M of general and administrative costs. That burn funds SPY003 and the rest of the SYRE pipeline.

The balance sheet, though, gives traders breathing room. Spyre reports $1.15B in cash, cash equivalents, and short‑term investments, plus $162.0M in pure cash. With total liabilities of just $71.9M and essentially no financial debt, SYRE is running a fortress‑style balance sheet for a small biotech. A current ratio of 18.5 means short‑term obligations are tiny compared with liquid assets.

Cash flow shows how the story is being financed. Operating cash flow in the period was -$69.9M, but SYRE offset that with $435.2M raised via stock issuance, boosting the cash pile. For traders, this reduces near‑term dilution worries, but negative returns on equity and assets highlight that all value still depends on trial success.

More Breaking News

On the chart, SYRE has been choppy but resilient, holding the high‑$80s to low‑$90s range even after the SPY003 headline. Intraday action shows tight trading around $89–$90, signaling consolidation as the market digests the data.

Why Traders Are Watching SYRE After SPY003

SYRE forced its way onto a lot of biotech watchlists with the SPY003 Phase 2 SKYLINE readout. Spyre Therapeutics delivered what traders always want in this space: a clear, binary win. The anti‑IL‑23 drug met its primary endpoint in moderately to severely active ulcerative colitis, with strong histologic improvement plus 20% clinical remission and 30% endoscopic improvement at 12 weeks. Safety looked class‑consistent and clean.

That would be enough on its own. But for SYRE, SPY003 is the missing piece. Positive Part A data completes proof‑of‑concept across all three inflammatory bowel disease mechanisms — SPY001, SPY002, and SPY003. Now Spyre shifts from single‑agent “does it work?” to combination Part B: “can a tailored combo change the standard of care?” That step often marks a real inflection point for small‑cap biotech names.

Yet, shares of SYRE traded modestly lower in premarket after the announcement. That tells you expectations were lofty. Many biotech traders had already priced in a decent chance of success. Others are simply waiting for confirmation in the combination arm and, eventually, Phase 3.

Layer on insider activity and the story gets more nuanced. On 2026/09/01, CEO Cameron Turtle sold 15,000 SYRE shares for about $1.31M, still holding 552,540 shares. CFO Scott Burrows sold 25,732 shares for roughly $2.28M and now controls 79,762 shares. Chief Legal Officer Heidy King‑Jones sold 28,399 shares for about $2.48M and retains 2,845 shares. Clustered selling after a strong run can spook short‑term traders, even when executives maintain sizable stakes.

At the same time, SYRE continues to behave like a company leaning into growth. Spyre granted new equity awards to a non‑executive hire and is presenting at multiple healthcare conferences in September 2026, giving management fresh stages to push the SPY003 narrative and highlight the wider immunology pipeline. Wedbush also flagged SYRE on an IL‑17‑focused conference call discussing psoriatic arthritis and axial spondyloarthritis, teeing up the late‑2026 Phase 2 readouts for SPY072 as another key catalyst. For active traders, that creates a defined calendar of events to track.

Conclusion

SYRE now sits at an interesting crossroad that experienced traders recognize well. On one side, Spyre Therapeutics has done the hard work of de‑risking its core IBD platform; SPY003’s Phase 2 SKYLINE win completes clinical proof‑of‑concept across three different mechanisms. On the other, the market reaction has been muted, and insider selling around early September adds a layer of headline noise and potential overhang.

From a fundamental angle, the SYRE balance sheet gives the company time. With more than $1.1B in cash and short‑term investments and no major debt, Spyre can push SPY003 combinations, progress SPY001 and SPY002, and still drive SPY072 toward its late‑2026 Phase 2 readouts in psoriatic arthritis and axial spondyloarthritis. The cost is clear in the numbers: steep negative returns and ongoing cash burn. That is the standard toll for trying to build a new immunology franchise.

For chart‑driven traders, SYRE’s tight range in the high‑$80s to low‑$90s after such major news screams “wait and see.” The stock is consolidating instead of chasing, which often sets up bigger moves when the next catalyst hits — whether that’s more SKYLINE data, conference commentary, or new Street coverage.

As Tim Sykes likes to remind his community, “The market doesn’t care about your opinion, it cares about catalysts and price action.” That mindset also reinforces risk management for anyone trading SYRE’s volatile catalysts — as millionaire penny stock trader and teacher Tim Sykes, says, “It’s better to go home at zero than to go home in the red.”. For now, SYRE has both: validated science in SPY003 and a full pipeline of upcoming events. This article is for educational and research purposes only, and traders should always do their own homework before making any trading decisions.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”